R

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Senior Manager - Clinical Quality Assurance

Regulatory & Quality (Life Sciences)Confirmed live in the last 24 hours
Full-timeTokyo, JapanNo salary listedIn-person

About the Job

Requirements

  • A bachelor's degree or higher in Pharmacy, Life Sciences, Biology, Chemistry, Engineering, Biotechnology, or a related scientific discipline is required.
  • At least 3 years of pharmaceutical-industry quality assurance experience related to GCP, GVP, and/or GPSP is required.
  • Knowledge of GCP, GVP, GPSP, applicable regulations, and industry best practices is required.
  • Experience supporting regulatory inspections and inspection-readiness activities is required.
  • Experience overseeing CROs, pharmacovigilance vendors, post-marketing surveillance vendors, and other GxP service providers is required.
  • Experience with audits, investigations, deviation management, CAPA management, and quality risk management is required.
  • Business-level English proficiency and native-level Japanese proficiency are required.
  • The ability to manage multiple priorities in a global, cross-functional environment is required.

Responsibilities

  • Lead and support regulatory inspections and inspection-readiness activities.
  • Provide risk-based quality oversight of CROs, laboratories, electronic Trial Master File providers, and other clinical vendors.
  • Partner with Clinical Development to promote GCP compliance.
  • Perform quality reviews of key documents, records, and operational processes.
  • Plan, conduct, and follow up on audits, inspections, and vendor audits.
  • Support investigations, deviation management, corrective and preventive action activities, and root cause analyses.
  • Provide quality guidance and support to clinical study teams.
  • Provide quality oversight of post-marketing surveillance activities conducted in accordance with GPSP requirements.
  • Establish, maintain, and continuously improve GPSP-related standard operating procedures and quality systems.
  • Perform quality reviews of processes, records, and deliverables associated with post-marketing surveillance activities.
  • Assess and manage GPSP-related deviations, corrective and preventive actions, quality events, and quality risks.
  • Support GPSP-related audits and regulatory inspections.
  • Oversee vendors supporting post-marketing surveillance activities and monitor their performance.
  • Collaborate with Pharmacovigilance, Medical Affairs, and Regulatory Affairs to ensure compliance with applicable requirements.
  • Support development, maintenance, and continuous improvement of the Japan Quality Management System.
  • Develop, maintain, and manage standard operating procedures and related quality documents.
  • Monitor regulatory developments and incorporate applicable requirements into quality systems.
  • Escalate significant quality risks and issues that may impact patient safety.
  • Establish and maintain inspection-readiness programs and inspection-management processes.
  • Promote a culture of quality and continuous improvement across the organization.

Desired Qualifications

  • Experience supporting product launch readiness and post-marketing quality activities within a marketing authorization holder organization.
  • Experience establishing, maintaining, or improving Quality Management Systems.
  • Experience working within outsourced or virtual development models.
  • Experience implementing Risk-Based Quality Management programs.
  • Experience supporting oncology clinical development programs.
  • Experience using electronic Trial Master File systems and supporting Trial Master File inspection-readiness activities.
  • Experience as a GxP auditor, including internal, vendor, and supplier audits.

About the Company

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Revolution Medicines develops precision oncology drugs focused on cancers driven by RAS mutations. Its RAS(ON) inhibitors are small molecules that bind the active form of RAS to block cancer signaling, with candidates like Daraxonrasib (RMC-6236), Elironrasib (RMC-6291), and Zoldonrasib (RMC-9805) advancing in global Phase 3 trials. The company funds its research through collaborations, royalties, and upfront funding, and has not yet marketed a product. Its goal is to bring effective RAS-targeted therapies to patients and advance multiple candidates through late-stage trials toward approval, supported by strong cash reserves.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Redwood City, CA
Founded
2014

Recently Posted Jobs

Explore more opportunities at Revolution Medicines

See more jobs